In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (< or =0.125 microg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 microg/ml; and all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by < or =0.125 microg/ml. Among the anaerobes tested, only fusobacteria (45%) required > or =4 microg of ABT-773/ml for inhibition. ABT-773 may offer a therapeutic alternative for sinus infections.
Goldstein
E J
EJ
R. M. Alden Research Laboratory Santa Monica-UCLA Medical Center, Santa Monica, California 90404, USA. EJCGMD@aol.com
Conrads
G
G
Citron
D M
DM
Merriam
C V
CV
Warren
Y
Y
Tyrrell
K
K
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001420:Bacteria, Aerobic / Q000187:drug effects* / Q000302:isolation & purification; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000302:isolation & purification; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D048628:Ketolides; D008443:Maxillary Sinus / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D011008:Pneumococcal Infections / Q000188:drug therapy; D011677:Punctures; D012852:Sinusitis / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D048628:Ketolides; D004917:Erythromycin; C405499:cethromycin